Atossa Therapeutics Inc (NASDAQ:ATOS)’s traded shares stood at 1.87 million during the last session, with the company’s beta value hitting 1.20. At the close of trading, the stock’s price was $1.80, to imply a decrease of -1.64% or -$0.03 in intraday trading. The ATOS share’s 52-week high remains $1.94, putting it -7.78% down since that peak but still an impressive 67.22% since price per share fell to its 52-week low of $0.59. The company has a valuation of $225.54M, with an average of 2.94 million shares in intraday trading volume over the past 10 days and average of 991.75K shares over the past 3 months.
Atossa Therapeutics Inc (NASDAQ:ATOS) trade information
After registering a -1.64% downside in the last session, Atossa Therapeutics Inc (ATOS) has traded red over the past five days. The stock hit a weekly high of 1.9400, dropping -1.64% in its intraday price action. The 5-day price performance for the stock is 7.14%, and 80.00% over 30 days. With these gigs, the year-to-date price performance is 104.55%. Short interest in Atossa Therapeutics Inc (NASDAQ:ATOS) saw shorts transact 8.48 million shares and set a 9.57 days time to cover.
Atossa Therapeutics Inc (ATOS) estimates and forecasts
Looking at statistics comparing Atossa Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Atossa Therapeutics Inc (ATOS) shares are 134.38% up over the last 6 months, with its year-to-date growth rate lower than industry average at -4.76% against 13.60%.
ATOS Dividends
Atossa Therapeutics Inc has its next earnings report out between March 29 and April 03. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Atossa Therapeutics Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Atossa Therapeutics Inc (NASDAQ:ATOS)’s Major holders
Atossa Therapeutics Inc insiders hold 0.04% of total outstanding shares, with institutional holders owning 13.00% of the shares at 13.00% float percentage. In total, 13.00% institutions holds shares in the company, led by Vanguard Group Inc. As of Jun 29, 2023, the company held over 5.68 million shares (or 4.51% of shares), all amounting to roughly $7.15 million.
The next major institution holding the largest number of shares is Blackrock Inc. with 2.9 million shares, or about 2.30% of shares outstanding. As of the market price on Jun 29, 2023, these shares were worth $3.65 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Atossa Therapeutics Inc (ATOS) shares. Going by data provided on Jun 29, 2023, Vanguard Total Stock Market Index Fund holds roughly 3.78 million shares. This is just over 3.00% of the total shares, with a market valuation of $4.76 million. Data from the same date shows that the other fund manager holds a little less at 1.66 million, or 1.32% of the shares, all valued at about 2.1 million.
